Skip to content

Study · Not a test of the peptide alone · 2011

6 results

Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Myöhänen TT, Tenorio-Laranga J, Jokinen B, Vázquez-Sánchez R, Moreno-Baylach MJ, García-Horsman JA, Männistö PT

British journal of pharmacology1 Aug 2011Cited by 45 (Europe PMC)

PMID21133893 (opens in a new tab)PMCIDPMC3166694 (opens in a new tab)DOI10.1111/j.1476-5381.2010.01146.x (opens in a new tab)PepBankPUB-21133893
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism

    In rats in a Matrigel plug assay, POP with thymosin beta‑4 significantly induced angiogenesis compared with thymosin beta‑4 alone.

    In plain wordsIn rats, adding POP to thymosin beta‑4 caused more new blood vessel growth than thymosin beta‑4 alone.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseIn vivo angiogenesis with POP and Tβ4
    Study

    ratn: not reported in source

    Matrigel plug assay in adult male rats
    Comparator
    Tβ4 alone
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    POP with Tβ4 significantly induced, while KYP-2047 effectively prevented, angiogenesis in both models compared with Tβ4 addition itself.
    1 context sentence
    Summary · context
    Angiogenesis of human umbilical vein endothelial cells was assessed in vitro using a 'tube formation' assay and in vivo using a Matrigel plug assay (BD Biosciences, San Jose, CA, USA) in adult male rats.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism

    In rats in a Matrigel plug assay, the POP inhibitor KYP-2047 prevented angiogenesis compared with thymosin beta‑4 alone.

    In plain wordsIn rats, the POP blocker KYP-2047 stopped new blood vessel growth compared with thymosin beta‑4 alone.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIn vivo angiogenesis with KYP-2047
    Study

    ratn: not reported in source

    Matrigel plug assay in adult male rats
    Comparator
    Tβ4 alone
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    POP with Tβ4 significantly induced, while KYP-2047 effectively prevented, angiogenesis in both models compared with Tβ4 addition itself.
    1 context sentence
    Summary · context
    Angiogenesis of human umbilical vein endothelial cells was assessed in vitro using a 'tube formation' assay and in vivo using a Matrigel plug assay (BD Biosciences, San Jose, CA, USA) in adult male rats.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In human umbilical vein endothelial cells, POP with thymosin beta‑4 significantly induced tube formation compared with thymosin beta‑4 alone.

    In plain wordsIn human blood vessel cells in a dish, adding POP to thymosin beta‑4 caused more tube formation than thymosin beta‑4 alone.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseIn vitro angiogenesis with POP and Tβ4
    Study

    humann: not reported in source

    HUVEC tube formation assay
    Comparator
    Tβ4 alone
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    POP with Tβ4 significantly induced, while KYP-2047 effectively prevented, angiogenesis in both models compared with Tβ4 addition itself.
    1 context sentence
    Summary · context
    Angiogenesis of human umbilical vein endothelial cells was assessed in vitro using a 'tube formation' assay and in vivo using a Matrigel plug assay (BD Biosciences, San Jose, CA, USA) in adult male rats.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In human umbilical vein endothelial cells, the POP inhibitor KYP-2047 prevented angiogenesis compared with thymosin beta‑4 alone.

    In plain wordsIn human blood vessel cells in a dish, the POP blocker KYP-2047 stopped tube formation compared with thymosin beta‑4 alone.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIn vitro angiogenesis with KYP-2047
    Study

    humann: not reported in source

    HUVEC tube formation assay
    Comparator
    Tβ4 alone
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    POP with Tβ4 significantly induced, while KYP-2047 effectively prevented, angiogenesis in both models compared with Tβ4 addition itself.
    1 context sentence
    Summary · context
    Angiogenesis of human umbilical vein endothelial cells was assessed in vitro using a 'tube formation' assay and in vivo using a Matrigel plug assay (BD Biosciences, San Jose, CA, USA) in adult male rats.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  5. 05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Mechanism

    In enzyme assays, thymosin beta‑4 was hydrolysed in sequence: proteases first cut it to peptides under 30 residues, then prolyl oligopeptidase acted.

    In plain wordsIn lab tests, enzymes broke thymosin beta‑4 down in two steps, and the second step used the enzyme POP.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableSequential hydrolysis of Tβ4
    Study

    n: not reported in source

    enzymatic hydrolysis assays (HPLC)
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    KEY RESULTS We showed the sequential hydrolysis of Tβ4: the first-step hydrolysis by proteases to <30-mer peptides is followed by an action of POP.
    1 context sentence
    Summary · context
    EXPERIMENTAL APPROACH We used HPLC for bioanalytical and an enzyme immunoassay for pharmacological analysis.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  6. 06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Mechanism

    In enzyme assays, prolyl oligopeptidase inhibited the first hydrolysis step of thymosin beta‑4.

    In plain wordsIn lab tests, the enzyme POP slowed the first step of thymosin beta‑4 breakdown.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreasePOP effect on first hydrolysis step of Tβ4
    Study

    n: not reported in source

    enzymatic hydrolysis assays (HPLC)
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Unexpectedly, POP inhibited the first hydrolysis step, revealing a novel regulation system.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.